Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Gross Margin (2018 - 2025)

Ultragenyx Pharmaceutical has reported Gross Margin over the past 8 years, most recently at 85.84% for Q4 2025.

  • Quarterly Gross Margin fell 373.0% to 85.84% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 83.8% through Dec 2025, down 245.0% year-over-year, with the annual reading at 83.8% for FY2025, 245.0% down from the prior year.
  • Gross Margin was 85.84% for Q4 2025 at Ultragenyx Pharmaceutical, up from 82.5% in the prior quarter.
  • Over five years, Gross Margin peaked at 96.39% in Q2 2021 and troughed at 79.42% in Q1 2025.
  • The 5-year median for Gross Margin is 90.03% (2022), against an average of 89.32%.
  • Year-over-year, Gross Margin surged 443bps in 2021 and then plummeted -565bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 95.79% in 2021, then fell by -1bps to 94.85% in 2022, then fell by -4bps to 90.69% in 2023, then fell by -1bps to 89.57% in 2024, then fell by -4bps to 85.84% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Gross Margin are 85.84% (Q4 2025), 82.5% (Q3 2025), and 86.18% (Q2 2025).